American Capital Management Inc buys $34,656,650 stake in Hologic (HOLX)

Hologic (HOLX) : American Capital Management Inc scooped up 5,590 additional shares in Hologic during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 1,031,755 shares of Hologic which is valued at $34,656,650.Hologic makes up approximately 3.14% of American Capital Management Inc’s portfolio.

Hologic opened for trading at $33.7 and hit $34.02 on the upside on Monday, eventually ending the session at $34, with a gain of 1.22% or 0.41 points. The heightened volatility saw the trading volume jump to 44,88,950 shares. Company has a market cap of $9,480 M.

Other Hedge Funds, Including , Simplex Trading added HOLX to its portfolio by purchasing 57 company shares during the most recent quarter which is valued at $2,062.Capstone Asset Management Co boosted its stake in HOLX in the latest quarter, The investment management firm added 1,100 additional shares and now holds a total of 26,576 shares of Hologic which is valued at $961,254. Hologic makes up approx 0.03% of Capstone Asset Management Co’s portfolio.Fjarde Ap-fonden Fourth Swedish National Pension Fund boosted its stake in HOLX in the latest quarter, The investment management firm added 6,811 additional shares and now holds a total of 73,433 shares of Hologic which is valued at $2,656,072. Hologic makes up approx 0.06% of Fjarde Ap-fonden Fourth Swedish National Pension Fund’s portfolio.

On the company’s financial health, Hologic reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.46. The company had revenue of $693.30 million for the quarter, compared to analysts expectations of $687.43 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.

Many Wall Street Analysts have commented on Hologic. Hologic was Downgraded by Needham to ” Hold” on Apr 28, 2016. Needham Upgraded Hologic on Jan 28, 2016 to ” Buy”, Price Target of the shares are set at $41.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.